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Abstract
Background: Coronary flow velocity reserve (CFVR) measured by transthoracic Doppler echocardiography of the
LAD is used to assess microvascular function but validation studies in clinical settings are lacking. We aimed to
assess feasibility, reproducibility and agreement with myocardial flow reserve (MFR) measured by PET in overweight
and obese patients.
Methods: Participants with revascularized coronary artery disease were examined by CFVR. Subgroups were examined
by repeated CFVR (reproducibility) or Rubidium-82-PET (agreement). To account for time variation, results were
computed for scans performed within a week (1-week) and for all scans regardless of time gap (total) and to
account for scar tissue for patients with and without previous myocardial infarction (MI).
Results: Eighty-six patients with median BMI 30.9 (IQR 29.4–32.9) kg ×m−2 and CFVR 2.29 (1.90–2.63) were included.
CFVR was feasible in 83 (97 %) using a contrast agent in 14 %. For reproducibility overall (n = 21) limits of agreement
(LOA) were (−0.75;0.71), within-subjects coefficient of variation (CV) 11 %, and reliability 0.84. For reproducibility within
1-week (n = 13) LOA were (−0.33;0.25), within-subjects CV 5 %, and reliability 0.97. Agreement with MFR of the LAD
territory (n = 35) was without significant bias and overall LOA were (−1.40;1.46). Agreement was best for examinations
performed within 1-week of participants without MI of the LAD-territory (n = 12); LOA = (−0.68;0.88).
Conclusions: CFVR was highly feasible with a good reproducibility on par with other contemporary measures applied
in cardiology. Agreement with MFR was acceptable, though discrepancy related to prior MI has to be considered. CFVR
of LAD is a valid tool in overweight and obese patients.
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Background
Coronary flow reserve (CFR) is an integrated measure of
coronary macro- and microvascular morphology and
function and is defined as the ratio of hyperaemic coron-
ary blood flow during maximum vasodilation of the cor-
onary vascular bed to resting coronary blood flow [1–3].
In absence of significant coronary artery stenosis, CFR is
considered a quantitative measure of coronary micro-
vascular function [2]. Coronary microvascular function is
increasingly being recognised as an important pathophysi-
ologic and prognostic factor in cardiovascular disorders
[2, 4]. Microvascular function is reduced in coronary
artery disease (CAD), even in territories without prior
coronary artery stenosis [5], and impaired microvascular
function carries a poor prognosis [4, 6].
Coronary flow velocity reserve (CFVR) measured by
transthoracic echocardiography (TTE) with spectral
Doppler measurement of coronary artery flow velocity
(CFV) is a non-invasive, non-ionising method and the
least expensive for measurement of coronary micro-
vascular function. CFVR has both diagnostic and prog-
nostic implications and may be a useful translational
tool for risk-stratification and to evaluate potential ef-
fects of intervention both in preclinical and clinical
proof-of-concept studies [3, 6–10].
The left anterior descending coronary artery (LAD) is
the more approachable coronary artery for measurement
of CFVR [11]. Agreement with intracoronary Doppler flow
wire has been established in small studies of unselected pa-
tients referred for coronary angiography (CAG) [12–15].
In a European cohort, 82 % of the patients diagnosed
with coronary artery disease (CAD) were overweight or
obese [16], and two thirds of the US population are esti-
mated to be overweight or obese [17]. Despite this,
CFVR by TTE Doppler of LAD has previously only been
validated against myocardial flow reserve (MFR) by posi-
tron emission tomography (PET), the non-invasive gold
standard method of myocardial perfusion, in ten healthy,
young, male subjects [18]. Thus with reference to the obes-
ity epidemic and an increasing interest in CFR as a measure
of coronary microvascular function in CAD [2, 4], valid-
ation of CFVR in overweight and obese patients is needed.
The aim of the study was therefore to validate CFVR by
TTE Doppler of the LAD in an overweight and obese co-
hort of stable and revascularized CAD patients in terms of:
1) Assessing feasibility,
2) Estimating reproducibility, and
3) Estimating agreement with MFR measured by PET.
Methods
Study participants
A total of 86 participants were recruited at the Depart-
ment of Cardiology, Bispebjerg University Hospital
among stable patients awaiting cardiac rehabilitation
(n = 16) and patients enrolled in the CUT-IT trial (n = 70),
a study of stable, overweight CAD patients [19]. All partic-
ipants had been revascularized according to guidelines
and had left ventricular ejection fraction above 35 %.
Patients were invited to participate in the feasibility study
and sub-studies without the investigators having prior
knowledge of the echocardiographic feasibility and quality.
All patients were included in the feasibility study (n = 86).
For the study of CFVR reproducibility, 31 participants
were randomly invited, seven declined (agreed to partici-
pate in the feasibility study only), measurement was not
feasible in three; thus 21 participants were examined
twice by the same experienced echocardiographer.
For the study on agreement with MFR, thirty-nine par-
ticipants underwent PET imaging; of them two were
excluded from the analysis due to technical errors (spe-
cifically protracted infusions resulting in too little tracer
infusion or mistiming of infusion and data acquisition)
resulting in too few counts during the stress part of the
examination, and in two CFVR was not feasible. Thus,
agreement between TTE and PET could be evaluated in a
total of 35 participants. Examinations were performed at
least 6 months after latest myocardial infarct (MI), Percu-
taneous Coronary Intervention (PCI) or Coronary Artery
Bypass Graft (CABG). Information about MI, PCI and
CABG were obtained from the medical records. An over-
view of the participants in the substudies is given in Fig. 1.
The study complies with the Declaration of Helsinki
and was approved by the Research Ethics Committee for
the Capital Region of Denmark (H-1-2009-127 and H-4-
2010-146). All participants gave informed written consent.
Coronary flow velocity reserve - CFVR
CFVR was measured by two experienced echocardiog-
raphers (RHO, MS) using a high-frequency broadband
transducer, either S6 with Vivid E9 (GE Healthcare,
Horten, Norway) or S8 with iE33 (Philips Medical Sys-
tems, Andover, MA, USA), with second harmonics as
previously described [8, 20]. All patients were instructed
to abstain from caffeine for 24 h before the examination.
With the patient in the left lateral decubitus position
LAD was visualized by colour Doppler along the anter-
ior interventricular sulcus as distal as possible with flow
towards the transducer; distal (cross-sectional view of
the apex by a modified, craniomedially displaced fore-
shortened apical 5- or 2-chamber view) or alternatively
mid-distal (modified low short-axis view) [21, 22]. Pos-
ition, angle and rotation of the probe were then opti-
mized for measuring the characteristic, prevalent
diastolic component of the biphasic flow in the LAD.
CFV was measured as the peak diastolic flow using a
pulsed-wave (PW) Doppler sample volume of 3–4 mm,
at rest and during myocardial hyperaemia induced by
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intravenous infusion 140 μg × kg−1 × min−1of adenosine
(2 min) or dipyridamole (6 min). This dosage of coronary
vasodilators have been shown to give similar responses in
CFV [23].
Before and during hyperaemia care was taken to en-
sure that measurements were done at the same angle on
the same segment of the LAD. If CFV was unobtainable
or the quality of the CFV envelope was considered inad-
equate or incomplete, an intravenous contrast agent, sul-
phurhexafluorid (SonoVue, Bracco Imaging Skandinavia
AB, Hisings Backa, Sweden) or perflutren (Optison, GE
Healthcare A/S, Brøndby, Denmark), was applied to en-
hance both the visualization of the colour Doppler delin-
eation of the LAD and the outer edge of the CFV PW
Doppler tracing. CFVR was calculated as the ratio be-
tween the highest CFV obtained during or after infusion
and resting CFV using a mean of three consecutive car-
diac cycles (6 to 10 if atrial fibrillation was present).
Analyses were done offline by an investigator blinded to
the other examinations.
We have previously reported inter and intra-observer vari-
ability of repeated off-line CFR readings with within-subject
coefficient of variation (CV) and limits of agreement (LOA)
of 5.5 % and ±0.21 (n= 39), and 7.5 % and ±0.29 (n= 10),
respectively [24]. An example of CFVR and MFR measure-
ment is shown in Figs. 2 and 3, respectively.
Myocardial flow reserve - MFR
The PET scan was performed on Siemens Biograph mCT/
PET 128 slice scanner (Siemens Healthcare, Erlangen,
Germany). Patients underwent serial rest followed by stress
imaging with Rubidium-82(82Rb) from a CardioGen82
82Sr/82Rb generator (Bracco Diagnostics Inc., Princeton,
NJ, USA). Our standard clinical protocol was used: An X-
ray scout view over the chest was performed for position-
ing followed by low-dose computed tomography (CT)
(120 kV, quality reference effective mAs = 11, rotation
0.5 s, pitch 1.5, collimation 16 × 1.2 mm) for attenuation
correction of the rest emission data.82Rb was infused intra-
venously at a flow rate of 50 mL ×min−1 and list mode 3D
data acquisition was started with the tracer infusion con-
tinuing for 7 min. Adenosine was infused as stated above.
Intravenous 82Rb infusion and list mode acquisition began
2.5 min after the start of adenosine infusion following the
same protocol as for rest. Registration between PET and
CT images was checked for evidence of patient motion
and manual adjustments were made before reconstruction
to correct for any minor motion. In cases of significant pa-
tient motion between PET and CT, an additional low-dose
CT could be acquired at the end of the study. Both rest
and stress dynamic images used for myocardial blood flow
(MBF) quantification were reconstructed into 18 time
frames (1 × 10, 8 × 5, 3 × 10, 2 × 20, 4 × 60 s) on a 128 ×
128 matrix and 2 × zoom (voxel dimensions 3.18 × 3.18 ×
2.03 mm) using 3D OSEM reconstruction (2 iterations, 21
subsets) with Siemens UltraHD-PET, a 6.5 mm Gaussian
postfilter, attenuation and scatter corrected (including
prompt gamma correction [25]). MBF quantification was
performed using Syngo MBF software (Siemens Health-
care, Erlangen, Germany) based on a single-compartment
model for 82Rb tracer kinetics [26]. Administered 82Rb-ac-
tivity was 1110 MBq during rest and stress. Thus, the radi-
ation dose for each patient was estimated to be 2.6 mSv in
total for rest and stress [27]. MFR was calculated as: MBF
during stress (mL ×min−1 × g−1)/MBF during rest (mL ×
min−1 × g−1), both globally for the left ventricle (MFRglobal)
Fig. 1 Overview of participants in the different parts of the study
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and for the LAD territory (MFRLAD) with reference to the
AHA 17 segment model [28].
Reproducibility of CFVR and agreement with MFR
To avoid spillover effects, infusion of adenosine/dipyrid-
amole was repeated with at least 24/72 h’ delay, respect-
ively. In an attempt to minimize influence of fluctuations
in CFR over time on measurement variability, we aimed at
performing repeated exams within seven days. Due to lo-
gistics, including a world-wide pause in CardioGen82 sup-
ply, this was only possible in 13 (62 %) and 20 (57 %) of
participants in the reproducibility and method agreement
(PET) sub-studies, respectively. Participants agreed to
avoid changes in medication during the study period. Re-
gional perfusion and thus MFRglobal was a priori assumed
to be affected by presence of scar-tissue from previous MI
[29]. Results are therefore given for the entire population,
stratified by time between examinations with cut-off at
one week and stratified by previous MI. For comparison
with MFRLAD, only participants with previous MI of the
LAD perfusion territory (MILAD) were included in the MI
subgroup. For comparison with MFRglobal, participants
with any previous MI were included in the MI subgroup.
We explored whether correction for Rate-pressure
product (RPP) would improve reproducibility of CFVR
and agreement between MFR and CFVR. RPP, systolic
blood pressure multiplied by heart rate, is a surrogate
for myocardial work [29]. Under normal circumstances
myocardial blood flow is determined by the work (O2
demand) of the heart via autoregulation. The autoregu-
lation of myocardial perfusion is uncoupled during
pharmacologically induced vasodilatory hyperaemia and
the correlation between RPP and perfusion is reduced.
In PET-studies, resting flow is often corrected for rest-
ing RPP and in some studies the usage is expanded to
the calculation of a supplemental RPP corrected MFR
[30]. Thus, a RPP corrected MFR and CFVR was calcu-
lated by multiplying MFR or CFVR by resting RPP and
dividing by 10,000.
Statistics
Unless stated otherwise, values are expressed as median
(interquatile range [IQR]) for continuous variables and
as count (%) for categorical variables. Continuous vari-
ables were evaluated by t-test or in case of non-normal
distribution Kruskal-Wallis equality-of-populations rank
test. Normal distribution was assessed graphically and by
Shapiro-Wilk test for normality. Equality of variances
was tested by Levenes test or in case of non-normal dis-
tribution Kolmogorov-Smirnov equality-of-distributions
test. Categorical variables were evaluated using χ2 or
Fishers exact test if an expected cell frequency was <5.
P < 0.05 in two-sided tests were considered statistically
significant. Confidence intervals (CI) refer to 95 % confi-
dence intervals. “Limits of agreement” (LOA) corre-
sponds to the 95 % prediction interval of differences and
was estimated for repeated examinations of CFVR and
for the comparison of CFVR and MFR, and presented as
mean difference (bias) and two times the standard devi-
ation of the differences (2SD) [31, 32]. Coefficient of
variation (CV) was calculated as the SD divided by the
population mean.
Fig. 2 Example of CFVR measurement by Doppler TTE. Lower pictures show measurement at rest. Upper pictures show measurement during hyperaemia.
Pictures to the left show the colour Doppler visualisation of the LAD. Pictures to the right show the pulsed wave Doppler measurement of the diastolic
peak coronary flow velocity (CFV). Coronary flow velocity reserve (CFVR) of this participant was 2.86 (corresponding MFRLAD was 2.57)
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Reliability relates the magnitude of the measurement
error in observed measurements to the inherent variability
in the “error-free” or “true” level of the quantity between
subjects and is defined by SD subjects’ true valuesð Þ
2
SD subjects’ true valuesð Þ2þ SD measurement errorð Þ2
¼ SD between subjectsð Þ2
SD between subjectsð Þ2þ SD within subjectsð Þ2 [33, 34].
Reliability for single measurements of CFVR with CI
was estimated from the reproducibility study as the
intra-class correlation coefficient (ICC) from a one-way
random-effects model.
For graphical representation of the correspondence
between the CFVR and MFR, in addition to the Bland-
Altman plot we used scatter plot with illustration of the
reduced major axis regression line, a useful summary
of data, defined as the line going through the intersec-
tion of the means with a slope given by the sign of the
Pearson’s correlation r and the ratio of the respective
standard deviations [35–37].
All analyses were performed in STATA/IC 13.1
(StataCorp LP, College Station, TX, USA).
Results
Feasibility of CFVR
Main participant characteristics, outlined in Table 1,
did not differ significantly between participants and
non-participants of the reproducibility and PET sub-
studies. Median age was 63 years and median BMI
was 30.9 kg × m−2.
CFVR showed high feasibility with successful measure-
ment in 83 (97 %) of 86 participants, a contrast agent
was applied in 12 (14 %). Median CFVR was 2.29, ran-
ging from 1.33 to 3.95. Sixty-two (75 %) participants
were examined with dipyridamole and 21 (25 %) with
adenosine. Average heart rate increased by 18 beats
per minute (P < 0.0001) during hyperaemia whereas
systolic and diastolic blood pressure did not change
significantly. No significant difference was observed
between dipyridamole and adenosine in mean CFVR
and response of heart rate or blood pressure. Median
resting RPP was 8016 (6950;9406) and did not correlate
with CFVR (P = 0.88).
Fig. 3 Example of MFR measurement by 82Rb PET. Lower row illustrates 82Rb-myocardial uptake at rest. Upper row illustrates 82Rb-myocardial
uptake during hyperaemia. MFRLAD of this participant was 2.57
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Reproducibility of CFVR
CFVR of the reproducibility study are shown in Fig. 4a-b as
scatter plot and difference vs mean (“Bland-Altman”) plot.
Measurement error was uniform over the range of CFVR.
Measures of reproducibility are summarized in Table 2.
The reproducibility of CFVR was overall acceptable with
a reliability of 0.84 (corresponding Pearson correlation coef-
ficient r = 0.83, P < 0.0001), (−0.75;0.71) and within-subject
CV of 11 %. Exams repeated within a week showed
better reproducibility with reliability of 0.97 (r = 0.97,
P < 0.0001), LOA (−0.33;0.25) and within-subject CV
of 5 %, which was significantly better than for exams
performed longer apart (P = 0.0001 for equal SD of
differences). The within-subject CV(CI) of CFV during
rest and hyperaemia was 15(11;26) % and 17(12;23) %
respectively.
In terms of characteristics listed in Table 1 patients ex-
amined within a week did not differ from patients with
examinations performed longer apart. Reproducibility
did not differ between patients with and without prior
MI (all: P = 0.44 and LAD-territory: P = 0.51) nor be-
tween examinations using adenosine and dipyridamole
(P = 0.50, n: 9 vs. 12).
CFR may be affected by baseline oxygen consumption.
However, difference in CFVR and RPP between repeated
exams did not correlate (P = 0.24) and correction of







Male gender 72 (84 %) 20 (95 %) 32 (91 %)
Age [years] 63 (57–67) 63 (58–67) 63 (60–69)
Height [m] 1.74 (1.69–1.78) 1.75 (1.72–1.82) 1.77 (1.70–1.77)
Weight [kg] 92.8 (85.6–100.5) 90.6 (82.1–97.4) 92.8 (85.4–101.0)
BMI [kg ×m−2] 30.9 (29.4–32.9) 29.0 (26.3–32.1) 30.8 (28.9–32.1)
MI 51 (59 %) 12 (57 %) 18 (51 %)
MILAD 26 (30 %) 8 (38 %) 12 (34 %)
CABG 18 (21 %) 8 (38 %) 9 (26 %)
Atrial fibrillation 7 (8 %) 2 (10 %) 2 (6 %)
Use of contrast 12 (14 %) 1 (5 %) 8 (23 %)
CFVR 2.29 (1.90–2.63) 2.27 (1.82–2.69) 2.39 (1.89–3.04)
Categorical and continuous variables expressed as count (%) and median
(IQR), respectively. BMI body mass index, MI myocardial infarction, LAD left
anterior descending artery territory, CABG coronary artery bypass graft, CFVR
coronary flow reserve by transthoracic Doppler echocardiography. No significant
differences between participants and non- participants in reproducibility
and PET study. P = 0.061(Fisher’s exact) for CABG in reproducibility study.
P = 0.057 (Fisher”s exact) for contrast usage in PET study
Fig. 4 Reproducibility of CVFR (n = 21). a Scatter plot of repeated measurements of CFVR (coronary flow reserve by transthoracic Doppler
echocardiography) performed in 1 week (blue closed circles) and more than a week apart (green open circles). Grey lines: full line marks equality
(no difference), dashed lines mark absolute differences of 0.5, and dotted lines represent absolute differences of 1 between repeated exams.
b Bland-Altman plot: Differences vs averages of repeated CFVR measurements performed in 1 week (blue closed circles) and more than a week
apart (green open circles). Limits of agreement for exams performed within a week (red dashed lines) and combined for all exams (green dotted lines) are
displayed together with corresponding mean differences (bias) for a week (red full line) and all differences (green dashed and dotted line)
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CFVR for resting RPP did not improve reproducibility in
terms of CV (P = 0.20).
Method agreement: CFVR vs. MFR
Thirty-five patients participated in the method agree-
ment study. Overall, MFRglobal was 2.46(0.61), MFRLAD
2.44(0.68) and CFVR 2.42(0.70). The means were not
different between participants with and without MI
(P = 0.24, 0.33 and 0.84). Agreement of CFVR with
MFRLAD is summarized in Table 3 and Fig. 5. The correl-
ation between CFVR and MFRLAD was modest but signifi-
cant (r = 0.46, P = 0.0053) and with no systematic bias
(Fig. 6). Agreement tended to be better for examinations
performed within a week (1-week vs. >1-week: P = 0.059
for equal SD of differences). In terms of characteristics
listed in Table 1, patients examined within a week did not
differ from patients with examinations performed longer
apart. Exclusion of participants with prior MI improved
correlation and agreement with PET (test of equal SD of
differences between CFVR and MFRLAD of No-MILAD vs.
MILAD: P = 0.024 for exams within a week and P = 0.38
totally). The agreement between methods was best for
participants without MI with exams performed within a
week (for No-MILAD: 1-week vs. >1-week: P = 0.0072) with
LOA= (−0.68;0,88) corresponding to CV = 17 % for
MFRLAD. Agreement with MFRglobal was as least as good;
overall 2SD (CV) was 1.32 (27 %), for scans performed
within a week 1.05 (22 %), and for scans within a week in
participants without prior MI of any perfusion territory
0.49 (11 %).
Agreement was not different between patients with
prior MI of the LAD-territory and MI of other territories
(MFRLAD: P = 0.59), nor was it affected by CABG-status
(MFRLAD: P = 0.78), or time between revascularization
and examination (MFRLAD: P = 0.91), which was med-
ian(range) 2(0,5-16) years. There was no difference in
mean subject SD of MFR with any of the strata MI or
time between examinations.
Resting RPP correlated with PET estimated resting
perfusion (LAD: r = 0.57, P = 0.0007), but not with MFR
(MFRLAD: P = 0.14). Correction for resting RPP did not
improve agreement between methods nor did differences
in resting RPP and differences between MFR and CFVR
correlate (MFRLAD: P = 0.61).
Discussion
The present study shows high feasibility of CFVR in a
population with generally limited echocardiographic acous-
tic window. Reproducibility of CFVR was good especially
when performed within a week. Agreement with PET was
overall modest, primarily because of poor agreement be-
tween methods in participants with prior MI whereas
agreement with PET was good in participants without
prior MI. Both the reproducibility and method agreement
sub-studies indicate that variability over time in CFR
should be taken into account e.g. when planning studies
with purpose of testing the effect of interventions on CFR.
Feasibility of CFVR
Although CFVR has low cost compared to other CFR
methods and advances in echocardiographic technology
have led to improvement in accessibility, CFVR has not
achieved wide routine use in clinical practice, primarily





Total (n = 21)







2SD 0.29 (0.16;0.42) 1.17 (0.43;1.92) 0.73 (0.49;0.97)
CV repeated exams [%] 7 (4;10) 25 (9;40) 16 (11;21)
CV repeated exams RPP
corrected [%]
12 (7;17) 17 (6;28) 14 (9;18)
CV of RPP [%] 12 (7;17) 18 (7;29) 14 (9;19)
Reliability, ICC 0.97 (0.91;0.99) 0.67 (0.05;0.92) 0.84 (0.65;0.93)
SD between-subjects 0.58 (0.39;0.85) 0.51 (0.27;0.97) 0.56 (0.40;0.78)
SD within-subjects 0.10 (0.07;0.15) 0.39 (0.24;0.63) 0.25 (0.19;0.34)
CV within-subjects [%] 5 (3;7) 16 (10;27) 11 (8;15)
Estimates of reproducibility for CFVR (coronary flow velocity reserve measured by
transthoracic Doppler echocardiography) for repeated measurement within 1 week,
more than 1 week, and for the total population of the sub-study. CFVR is mean
(SD), all other variables are estimate (CI). 2SD Two times standard deviation
of differences, CV coefficient of variation, ICC intra-class correlation coefficient,
RPP rate-pressure product, SD standard deviation
Table 3 Agreement between CFVR measured by echocardiography and MFR measured by PET of the LAD territory (n = 35)
1 week Total
MFRLAD – CFVR No-MILAD (n = 12) MILAD (n = 8) Combined (n = 20) No-MILAD (n = 23) MILAD (n = 12) Combined (n = 35)
Pearson correlation, r 0.71 (0.0090) 0.43 (0.29) 0.57 (0.0086) 0.49 (0.018) 0.44 (0.16) 0.46 (0.0053)
Mean difference 0.11 (−0.33;0.17) −0.23 (−0.91;0.45) −0.14 (−0.42;0.13) 0.05 (−0.40;0.17) −0.02 (−0.55;0.53) 0.03 (−0.22;0.27)
2SD 0.79 (0.42;1.16) 1.63 (0.60;2.66) 1.17 (0.77;1.56) 1.32 (0.91;1.73) 1.67 (0.89;2.45) 1.43 (1.07;1.78)
CV [%] 17 (9;25) 31 (12;51) 24 (16;32) 27 (19;36) 34 (18;51) 29 (22;37)
Values are given as estimate (P or CI). CFVR Coronary flow velocity reserve by echocardiography of the LAD, MFRLAD Myocardial flow reserve of the LAD territory
by PET, MILAD Myocardial infarction of the LAD territory, 2SD Two times standard deviation of differences, CV coefficient of variation
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due to concerns of feasibility in representative patient
populations and validity of the measures achieved [38].
We found a feasibility of 97 % in an unselected group of
patients with a median BMI above 30 kg ×m−2. This feasi-
bility is comparable to those previously obtained in patient
populations not excluding overweight subjects. A large
multicentre study comprising 1544 patients had a feasibil-
ity of 92 % (exclusive of 2 % for whom examination was
stopped prematurely because of side-effects) with contrast
used in 36 % [7]. One study with a population mean BMI
of 30 (n = 38) reported feasibility of 92 % with 10 % requir-
ing contrast usage and other studies not reporting on
body habitus have achieved success rates up to 100 %
(n = 124) [9, 39]. In comparison feasibility of 95 and
98 % has been reported for mitral annular velocities
as measured by speckle tracking and PW tissue Doppler,
respectively [40].
Reproducibility of CFVR
LOA of CFVR repeated within a week in the present
study is almost identical to LOA of 0.32 in a study of 13
patients referred for CAG in whom CFVR was repeated
with a delay of one hour, and to LOA of 10 % in hyper-
tensive patients (n = 8) examined 3–5 days apart, as well
as a CV of 6 % reported for lean healthy subjects (n = 8)
[12, 18, 41]. In fact the reproducibility could not be ex-
pected to be better, since the present within-subject CV,
corresponding to error of measurement, is on par with
the previously reported observer variability of repeated
off-line readings [24]. The within-subject CV tends to be
higher for CFV than CFVR, which probably is due to
the fact that minor differences between examinations
that may cause difference in measured CFV between ex-
aminations (e.g. placement of probe or sample volume
and Doppler angle to the flow), tends to have no
Fig. 5 Method agreement CFVR vs MFRLAD. “Bland-Altman plot”: Differences vs averages of myocardial flow reserve (MFR) measured by PET of the
LAD-territory (MFRLAD) versus coronary flow velocity reserve (CFVR) measured by transthoracic Doppler echocardiography of the LAD. a include all
participants and (b) display measurements of participants with no prior myocardial infarction (No-MI) of the LAD territory. Examinations performed
in a week are marked by closed squares and triangles for participants without and with prior myocardial infarction of the LAD territory,
respectively. Examinations performed more than a week apart are marked by open squares and triangles for participants without and with
prior myocardial infarction of the LAD territory, respectively. Limits of agreement for exams performed within a week (red dashed lines) and
combined for all exams (green dotted lines) are displayed together with corresponding mean differences (bias) for a week (red full line) and all
differences (green dashed and dotted line)
Olsen et al. Cardiovascular Ultrasound  (2016) 14:22 Page 8 of 12
significant impact on CFVR as long as it is kept constant
during the same examination.
CFVR seems to perform as well as several other mea-
sures applied in clinical practice. The reproducibility of
CFVR repeated within a week is comparable to measures
as LVEF by Simpson biplane method, M-Mode mitral an-
nular excursion, and peak early mitral annular velocity (e’)
(CV 5–12 %) in terms of CV [40, 42, 43]. Similarly, we find
the overall reproducibility of CFVR to be at least as good
as for MFR by PET (CV range 17 to 26 %) [30, 44–46].
The good reproducibility of CFVR has practical impli-
cations as it underpins the usefulness of serial evaluation
of CFVR e.g. before and after revascularization, or as an
outcome measure in clinical as well as preclinical trials
of e.g. drug therapy on coronary microvascular function.
Reliability is an estimate of the proportion of all variation
that is not due to measurement error [33, 34]. For labora-
tory measurements a reliability above 0.90 is desirable [34].
We report reliability for examinations repeated within a
week that is significantly higher, meaning that more than
90 % of the variability in the measurements of CFVR was
due to genuine differences in CFVR between the partici-
pants. Reliability is influenced by the heterogeneity (vari-
ance) of the study population with regard to the measured
parameter, i.e. the greater between-subjects variance the
greater reliability. As we have made no selection on
CFVR values, the reported reliability is representative
for a population of overweight and obese revascularized
and stable CAD patients. The relatively high reliability
of CFVR makes it suited for distinguishing patients on
this parameter. This is also reflected in its ability to
prognosticate [6].
Method agreement: CFVR vs. MFR
There are obvious differences between methods of esti-
mating CFVR by TTE Doppler and MFR by PET. CFVR
is the ratio of peak diastolic flow velocities whereas MFR
estimates the perfusion volume-velocity per myocardial
tissue mass (mL × g−1 × min−1) for the entire heart cycle.
Further, the methods can be affected be different fac-
tors. For example, a change between rest and hyper-
aemia in the calibre of the artery where the sample
Fig. 6 Method agreement MFRLAD CFVR vs CFVR. Scatter plot of myocardial flow reserve (MFR) measured by PET of the LAD-territory (MFRLAD)
versus coronary flow velocity reserve (CFVR) measured by transthoracic Doppler echocardiography of the LAD. Examinations performed in a week
are marked by blue closed squares and triangles for participants without and with prior myocardial infarction of the LAD territory, respectively.
Examinations performed more than a week apart are marked by green open squares and triangles for participants without and with prior myocardial
infarction of the LAD territory, respectively. Full red line: represents the reduced major axis, the line going through the intersection of the means with
a slope given by the sign of the Pearson’s correlation r and the ratio of the respective standard deviations. Grey lines: dashed line marks
equality (no difference), dotted lines mark absolute differences of 0.5 between measurements
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volume is placed would have effect on the flow velocity
and the measured CFVR. Whereas, 82Rb extraction can be
decreased by severe acidosis, hypoxia, and ischemia; thus
in addition to blood flow, 82Rb uptake could be affected
by metabolism and myocardial cell integrity [47].
We found 2SD ranging from 0.49 to 1.67. For com-
parison, we have knowledge of only one study; Saraste
et al. examined CFVR and MFRLAD in 10 young, healthy
participants with a mean delay of 13 days, and reported
LOA corresponding to mean difference (2SD) of −0.20
(1.03) [18]. Thus, agreement for obese CAD patients per-
formed within a week, −0.14(1.17), is of comparable mag-
nitude to that of the healthy, lean and young subjects.
Agreement between CFVR and MFRglobal was as good
as for CFVR and MFRLAD. Possible explanations are that
microvascular dysfunction is a process that affects the
global myocardium and the reproducibility of regional
estimates tend to be poorer than for global estimates in
the majority of studies [30, 44–46, 48].
In concordance with our findings for agreement be-
tween CFVR and MFR, reproducibility of MFR is in gen-
eral not improved by correction for RPP, nor is it the
tradition to correct CFVR for RPP [30, 44–46, 48].
Agreement between any two methods depends on and
is limited by the repeatability or reproducibility of both
methods [31]. We did not evaluate the reproducibility of
MFR but it has been assessed previously by others. Re-
producibility seems to be similar for 15O-water, 13N-am-
monia or 82Rb, and without any obvious difference
between studies of delayed or immediately repeated
exams [30, 44–46, 48, 49]. Sdringola et al. evaluated the
reproducibility of MFR using 82Rb in 107 healthy sub-
jects with a median delay of 22 days between repeated
exams. For global estimates (regional being of comparable
magnitude) they found reproducibility corresponding to
LOA +/−38 % and +/−51 % of mean MFR, equivalent
to absolute differences of 1.6 and 2.0 in what they termed
“true” and “not-true normals”, respectively [44]. Manabe
et al. applied 82Rb in repeated exams separated by an hour
and found reproducibility corresponding to LOA of +/−1.6
(37 %) in15 healthy participants [46].
In this context, our overall findings of agreement between
CFVR and MFRLAD and MFRglobal must be considered to
be acceptable.
The acceptable agreement between CFVR and MFR can
have practical implications in the clinical setting as CFVR
as a non-invasive, non-ionising method with prompt avail-
ability and lower cost would be preferable.
Our data of both CFVR reproducibility and method
agreement indicate that variability over time in CFR
should be taken into account e.g. when planning studies
with purpose of testing the effect of interventions on
CFR. That CFR and microvascular function is a dynamic
parameter is also illustrated by previous findings of
improvement in CFR early (days) after stenting both in
patients with and without MI, with further improvement
in some but not all patients after 3–6 months [50–52],
which can relate to myocardial recovery [52], and in-
stent restenosis [9, 51]. Likewise, improvement in CFR
has been illustrated from 1 to 6 months after CABG
[53]. The post interventional improvement could also be
influenced by rehabilitation efforts such as exercise and
weight-loss [8]. In attempt to reduce the potential effect
of recovery after MI, PCI, in-stent restenosis and CABG
we included only participants in stable phase at least six
months after PCI, MI or CABG.
Limitations
We instructed participants and they agreed to abstain
from caffeine before examinations, but we did not asses
the validity of this by means of laboratory testing of caf-
feine levels as it would normally not be done in a clin-
ical setting. If any participant should not have complied
with the instructions on caffeine, it must be considered
a random effect and as so it would tend to decrease the
estimated reproducibility and agreement. It is a limitation
of the method agreement substudy that only patients
with revascularized stenosis were included, however the
focus of the present study was on CFR as a measure of
microvascular function and not on estimation of sten-
osis severity. We did not repeat assessment of coronary
anatomy immediately before trial start. However, exer-
cise ecg and stress echocardiography were performed at
inclusion and these were without limiting angina or
signs of ischemia in all patients included in the study.
This was also illustrated by the fact that CFVR of LAD
had as good agreement with MFRglobal as with MFRLAD.
CFVR was measured as distal as possible, in order to
measure distal to grafts to the LAD. Accordingly, we
consider CFVR a measure of microvascular function also
in the participants with CABG.
Patients with previous CABG often have complicated
coronary anatomy and thus, it can be difficult to define
“matched” myocardial region perfused by the LAD vs.
competitive flow from grafts, LCX or RCA for compari-
sons with CFVR [54]. We did not take into account the
exact coronary anatomy from CAG of the individual
participant, and the regional MFR was estimated by our
clinical routine practice from the standard region applied
by the software. However, our agreement obtained in non-
MI participants within a week is not far from agreement
between repeated readings (the same examination) of MFR
performed with different software-packages (LOA +/−0.3,
n = 90 patients) or between a novice and an expert reader
using identical software (LOA +/−0.3, n = 30) [55, 56].
The sample size was limited and it was not the pur-
pose of the study to estimate differences in agreement
between subgroups (ie MI vs no-MI, and PCI vs CABG).
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Conclusions
In conclusion, CFVR had high feasibility with the poten-
tial use of a contrast agent. Reproducibility was good
compared to previous estimates for lean and healthy
subjects, and compared to reproducibility of other well-
known measures used in the field of cardiology. Accept-
able agreement with PET MFR was achieved, though
discrepancy related to prior MI has to be considered and
evaluated in future studies. Our study thus confirms that
CFVR by TTE is a feasible and valid method for asses-
sing microvascular function in stable and revascularized
overweight and obese patients with CAD.
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